Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab
Fighting off a flank attack in the courts by attorneys for rival Shire, Roche says it was flagged for the FDA’s inside regulatory track for emicizumab (ACE910), a new drug for hemophilia A.
The Swiss pharma giant says the FDA has now set February 23 as its deadline for a decision on this drug, lopping four months off the process in recognition of its potentially game-changing status in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
